<div id="readability-page-1"><p>GH Research PLC (NASDAQ:GHRS - Get Free Report) has received an average recommendation of &#34;Moderate Buy&#34; from the eleven research firms that are  covering the firm, Marketbeat Ratings reports. One investment analyst  has rated the stock with a sell recommendation, one  has given a hold recommendation and nine have given a buy recommendation to  the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $40.1250.</p><ul><li>3 Fast-Growing Stocks Analysts See Doubling in Price</li></ul><p>Several research firms have commented on GHRS. Needham &amp; Company LLC lifted their target price on shares of GH Research from $31.00 to $32.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, March 6th. Royal Bank Of Canada raised their price objective on GH Research from $33.00 to $40.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, January 23rd. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of GH Research in a research report on Tuesday, April 21st. Guggenheim  set a $34.00 target price on GH Research and gave the company a &#34;buy&#34; rating in a research note on Tuesday, March 10th. Finally, Wolfe Research  set a $39.00 target price on GH Research in a research report on Tuesday, January 6th.</p><p><b>Read Our Latest Research Report on GH Research</b></p><h2>Institutional Inflows and Outflows</h2><p>Large investors have recently modified their holdings of the stock. Lynx1 Capital Management LP boosted its position in shares of  GH Research by 27.5% in the third quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company's stock worth $122,997,000 after acquiring an additional 1,854,238 shares during the last quarter.  RTW Investments LP increased its position in  GH Research by 6.5% during the fourth quarter. RTW Investments LP now owns 5,933,815 shares of the company's stock worth $75,359,000 after purchasing an additional 364,251 shares during the last quarter.  Avoro Capital Advisors LLC purchased a new position in  GH Research during the fourth quarter worth approximately $22,860,000.  Millennium Management LLC raised its stake in  GH Research by 324.1% during the third quarter. Millennium Management LLC now owns 863,602 shares of the company's stock worth $12,350,000 after purchasing an additional 659,957 shares during the period.  Finally, Jefferies Financial Group Inc. boosted its holdings in shares of  GH Research by 0.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 712,300 shares of the company's stock valued at $9,046,000 after purchasing an additional 2,988 shares during the last quarter. 56.90% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>GH Research Trading Down 1.9%</h2><p>NASDAQ:GHRS opened at $21.28 on Wednesday. GH Research has a 12-month low of $9.46 and a 12-month high of $24.66. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of -26.60 and a beta of 1.27. The company's 50-day moving average is $16.16 and its two-hundred day moving average is $15.08. </p><p>GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings results on Friday, March 6th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.06.  On average, equities research analysts forecast that  GH Research will post -1.52 earnings per share for the current fiscal year. </p><h2>GH Research Company Profile</h2> (Get Free Report)<p>GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.  </p><p>The firm's lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than GH Research</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0hSUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0hSUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in GH Research Right Now?</h2><p>Before you consider GH Research, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.</p><p>While GH Research currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GHRS

ARKG

<p>GH Research PLC (NASDAQ:GHRS) has received an average recommendation of "Moderate Buy" from eleven research firms. One analyst rated it as a sell, one as hold, and nine as buy. The average 12-month price target is $40.13. Notable price target increases include Needham raising it to $32, and Royal Bank of Canada to $40. The stock is currently trading at $21.28, with a market cap of $1.32 billion. GH Research focuses on developing treatments for neuropsychiatric disorders using psychedelic-inspired compounds.</p>

Market Beat

GH Research

Ark Genomic Revolution ETF

VG Health

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

SPDR S&P Biotech

ROYAL BANK OF CANADA

Millennium

Jefferies Financial

GH Research PLC (NASDAQ:GHRS) Given Average Recommendation of "Moderate Buy" by Brokerages